



(51) International Patent Classification:

C07K 14/31 (2006.01) C07K 1/22 (2006.01)
C07K 16/06 (2006.01) C07K 17/00 (2006.01)
B01D 15/38 (2006.01)

(21) International Application Number:

PCT/EP2024/068688

(22) International Filing Date:

03 July 2024 (03.07.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2350960-7 14 August 2023 (14.08.2023) SE

(71) Applicant: **CYTIVA BIOPROCESS R&D AB** [SE/SE];
Björkgatan 30, 751 84 Uppsala (SE).

(72) Inventors: **BJÖRKMAN, Tomas**; Cytiva, Björkgatan 30,
751 84 Uppsala (SE). **PALMGREN, Ronnie**; Cytiva,
Björkgatan 30, 751 84 Uppsala (SE). **HANSSON, Jes-**
per; Cytiva, Björkgatan 30, 751 84 Uppsala (SE). **KANE,**


Christopher; Cytiva, Björkgatan 30, 751 84 Uppsala (SE).
RAHMAN, Mahafuzur; Cytiva, Björkgatan 30, 751 84
Uppsala (SE). **SCHOURI, Samir**; Cytiva, Björkgatan 30,
751 84 Uppsala (SE). **ANDER, Mats**; Cytiva, Björkgatan
30, 751 84 Uppsala (SE). **JONSSON, Andreas L M**; Cy-
tiva, Björkgatan 30, 751 84 Uppsala (SE). **JINGXIN HU,**
Francis; Cytiva, Björkgatan 30, 751 84 Uppsala (SE).

(74) Agent: **DÉMOULIN, Lotta** et al.; Cytiva Sweden AB,
Björkgatan 30, 751 84 Uppsala (SE).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: VH3 BINDING SEPARATION MATRIX AND METHODS FOR USING THE SAME

Fig. 8A



(57) Abstract: The present invention provides for a separation matrix for purification of antibodies or antibody fragments comprising at least one VH3 chain, said separation matrix comprising a VH3 binding ligand coupled to a porous support. Also provided is a method for isolation of antibodies or antibody fragments comprising at least one VH3 chain using the above-mentioned separation matrix. Additionally, there is provided a method for separation of bispecific antibodies or antibody fragments comprising one VH3 chain from variants of the antibody or antibody fragment comprising two VH3 chains or no VH3 chain, using the above-mentioned separation matrix.

[Continued on next page]

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*